BACKGROUND There is limited evidence on the safety and efficacy of spironolactone in the treatment of women with acne. Thus, for many dermatologists spironolactone remains an alternative rather than a mainstay treatment for female patients with acne. METHODS An electronic medical records search tool was used to select data from a group of women who received spironolactone to treat acne and we...

Remodeling of the cerebral vasculature contributes to the pathogenesis of cerebral ischemia. Remodeling is caused by increased smooth muscle proliferation and may be due to an increase in the responsiveness of vascular cells to epidermal growth factor (EGF). Aldosterone is a risk factor for stroke, and the literature suggests it may play a role in increasing the expression of the receptor for E...

Studies were carried out in 14 patients with primary aldosteronism (1°A) to examine the mechanism(s) by which spironolactone reduces arterial pressure. Measures that produced salt and water depletion were found to consistently reduce arterial pressure. Plasma volume and arterial pressure correlated directly and significantly, r =+0.509 (P <0.001), whether pressure was reduced by spironolactone ...

Studies were carried out in 14 patients with primary aldosteronism (1°A) to examine the mechanism(s) by which spironolactone reduces arterial pressure. Measures that produced salt and water depletion were found to consistently reduce arterial pressure. Plasma volume and arterial pressure correlated directly and significantly, r =+0.509 (P <0.001), whether pressure was reduced by spironolactone ...

Female pattern hair loss (FPHL) results from a combination of hormones, aging, and genetics, is the most common type alopecia in women. Topical minoxidil remains only US Food Drug Administration (FDA)-approved treatment for this condition, although numerous other therapies have demonstrated efficacy recent years. Spironolactone, weak androgen receptor inhibitor, largely effective at various dos...

Spironolactone in Resistant Hypertension To the Editor: The recent article by Chapman1 and the accompanying editorial by Goodfriend2 provide an evidence base for an increased use of spironolactone in patients with resistant hypertension. The usual definition of resistant hypertension states that a diuretic should have been included in the regimen of 3 or more drugs. In this Anglo-Scandinavian C...

Aldosterone receptor antagonist, spironolactone, has been shown to prevent remodeling of the heart in several models of left ventricular hypertrophy. The aim of the present study was to determine whether the treatment with spironolactone can prevent hypertension, reduction of tissue nitric oxide synthase activity and left ventricular (LV) and aortic remodeling in N(G)-nitro-L-arginine methyl es...

Studies were carried out in 14 patients with primary aldosteronism (1°A) to examine the mechanism(s) by which spironolactone reduces arterial pressure. Measures that produced salt and water depletion were found to consistently reduce arterial pressure. Plasma volume and arterial pressure correlated directly and significantly, r =+0.509 (P <0.001), whether pressure was reduced by spironolactone ...

In a crossover study 32 patients with hypertension were randomly allocated to treatment with spironolactone 200 mg/day for two months, propranolol 320 mg/day for two months, and a combination of both drugs at half the dose. Between the treatments placebo was given for two months. Both spironolactone and propranolol lowered the blood pressure significantly in both positions. The initial plasma r...

OBJECTIVES This study investigated the influence of baseline and worsening renal function (WRF) on the efficacy of spironolactone in patients with severe heart failure (HF). BACKGROUND Renal dysfunction or decline in renal function is a known predictor of adverse outcome in patients with HF, and treatment decisions are often on the basis of measures of renal function. METHODS We used data f...